Abeona Therapeutics Signals Strong Early ZEVASKYN Launch

Abeona Therapeutics Inc ((ABEO)) has held its Q1 earnings call. Read on for the main highlights of the call.

Abeona Therapeutics’ latest earnings call struck an overall optimistic tone, with strong early commercial traction for ZEVASKYN offsetting heavier spending and cash burn. Management highlighted accelerating revenue, expanding treatment capacity and robust payer coverage, while acknowledging operational bottlenecks and higher costs tied to the launch and a new oncology program.

Early Revenue Surge From ZEVASKYN

Net product revenue climbed to $8.7 million in Q1 2026, driven by three commercially insured ZEVASKYN patients and marking a roughly 262% jump from $2.4 million in Q4 2025. This sharp quarter‑over‑quarter acceleration, though from a small base, signals that early demand is converting into meaningful top‑line growth.

Growing Patient Volume And QTC Footprint

Since launch, five patients have been treated, including one in Q4 2025, three in Q1 2026 and one already in the current quarter, with more in the funnel. Abeona now has six Qualified Treatment Centers active across the U.S., is targeting seven this year and ultimately sees room for about nine to ten centers, each expected to reach a cadence of roughly one patient per month.

Payer Coverage Underpins Market Access

Published policies for ZEVASKYN now cover 95% of commercially insured lives, removing a key barrier for prescribers and patients. Management reported no patient attrition or final payer denials so far, suggesting that payers are accepting the therapy’s value proposition in the early commercial phase.

Manufacturing Reliability And Clinical Execution

Commercial manufacturing turnaround is typically 23–24 days, with an observed range of 23–26 days, providing a relatively predictable operational window once biopsies are obtained. Crucially, every valid biopsy has produced therapeutic cell sheets, most with double‑digit yields, and there have been no harvest failures, supporting confidence in scalability.

Pipeline Expansion With PSMA SIR-T (ABO-701)

Abeona broadened its pipeline by in‑licensing a PSMA‑directed SIR‑T oncology asset, ABO‑701, for a $7 million upfront payment and about $1 million in milestones through Phase I. A pre‑IND meeting is set for June 2026 with an IND and first‑in‑human trial targeted for the second half of 2027, after which Abeona can either co‑develop the asset 50/50 or license it out for royalties.

R&D Rebalancing And Capital Discipline

R&D expense was $9.6 million in Q1 2026, slightly below $9.9 million a year earlier despite the $7 million PSMA upfront, implying underlying R&D declined as some costs shifted to inventory post‑approval. Management emphasized that incremental spend on the PSMA program should remain minimal in the near term, in the low single‑digit millions for the rest of the year.

Strong Field Demand And Physician Engagement

Commercial teams see robust interest, with a near‑term pool of more than 100 potential patients identified across QTCs and community practices. The company is in active discussions with 45 referring physicians, and feedback from QTCs suggests that processes are improving as centers gain experience with the therapy.

Improving Gross-To-Net Mix And Revenue Quality

Q1 revenue was entirely from commercial payers, a shift from earlier quarters with more Medicaid exposure and typically heavier discounts. Abeona expects gross‑to‑net deductions to settle in the mid‑ to upper‑teens percentage range as volumes grow and the payer mix stabilizes, supporting higher‑quality revenue.

Wider Net Loss On Launch And Licensing Costs

The company posted a net loss of $17.1 million, or $0.30 per share, in Q1 2026 versus $12.0 million, or $0.24 per share, a year earlier, an increase of 42.5%. Management tied the deeper loss mainly to investments in commercialization and the $7 million ABO‑701 license charge, which they frame as strategic rather than structural deterioration.

Operating Expense Inflation Led By SG&A

Selling, general and administrative expenses nearly doubled to $19.5 million, up $9.7 million year over year, reflecting the build‑out of the commercial organization. The increase was driven largely by $5.4 million of personnel and stock‑based compensation and $1.9 million of engineering runs associated with scaling the launch.

Cash Burn And Balance Sheet Snapshot

Cash, cash equivalents and short‑term investments fell to $168.3 million at the end of Q1 from $191.4 million at year‑end 2025, a decline of about 12%. While the current balance provides a buffer to fund operations and early pipeline work, the trajectory of cash burn will remain a critical metric for investors as the launch scales.

Insurance And Medicaid Create Timing Friction

Management noted that winning approvals for a high‑cost gene therapy involves lengthy, case‑by‑case reviews, particularly for out‑of‑state Medicaid patients. While these processes introduce timing variability and delay revenue recognition, the team stressed that there have been no final denials, which mitigates concerns about structural access barriers.

Long And Variable Biopsy Lead Times

From QTC activation to first patient biopsy, timelines have ranged from about two months to as long as six to seven months, with an estimated average of four to five months. This variability complicates near‑term forecasting, making quarterly revenue cadence harder to predict even as underlying demand appears healthy.

Cost Of Sales Rising With Scale

Cost of sales climbed to $2.7 million in Q1 2026 from $1.0 million in Q4 2025 as the number of commercial treatments rose from one to three. Investors should expect these costs to grow further as volumes ramp, though the company aims to offset this via operational efficiencies and higher throughput per center over time.

Complex Path To QTC Activation

Bringing a new QTC online requires coordination among multidisciplinary clinical teams, management, legal and contracting, as well as quality and operational onboarding. Abeona said this process can take several months to more than a year, limiting how quickly it can expand geographic reach and capacity.

Guidance And Outlook For The Remainder Of 2026

Looking ahead, management expects the current quarter to include one treated patient already, one in manufacturing and six more slated for biopsies, with manufacturing cycles of roughly 23–24 days suggesting some may convert into Q2 revenue. They reiterated targets for seven QTCs in 2026, longer‑term capacity of nine to ten centers at about one patient per month each, gross‑to‑net in the mid‑ to upper‑teens, minimal additional PSMA R&D this year and even the possibility of achieving monthly profitability as early as June, depending on biopsy and treatment cadence.

Abeona’s earnings call portrayed a company in the early but promising stages of commercial execution, with ZEVASKYN gaining traction, payers largely on board and manufacturing running smoothly. The trade‑off is higher near‑term losses, rising operating costs and operational complexity, leaving investors to watch whether patient volumes and center throughput can scale fast enough to justify the spending and sustain momentum.